Oncology
Driving your oncology brand with stage, line of therapy, and indication-specific strategies, optimized and aligned to evolving pathways and standards of care.
In today’s dynamic oncology landscape—where biomarker stratification, pathway-driven care, and shifting reimbursement models are reshaping access—we help you stay ahead.
Our expertise spans route-of-administration strategies, site-of-care dynamics, and evolving specialty distribution models. We deliver strategy development, value demonstration, and stakeholder engagement anchored in real-world oncology insights and deep clinical and economic expertise. From navigating buy-and-bill complexities to designing impactful patient support programs, we build access solutions that meet the demands of today’s oncology market.
pharmaceutical clients
oncology products supported
new oncology drug launches and label expansions

Helping you navigate challenges
As a trusted oncology partner, we have a proven track record of bringing complex therapies—like MET targeted therapies, oral oncolytics, and liquid and solid tumor treatments—to market.
From early development through loss of exclusivity, we support clients through our approach of scientific rigor, deep market access expertise, and strategies tailored to today’s evolving approval landscape.

Our Expertise & Our People
Our oncology expertise is grounded in deep regulatory, clinical, and commercial experience.
Our team includes former FDA reviewers, HEOR leads, oncology brand executives, access consultants, board-certified oncology pharmacists (BCOPs), and former decision makers from top US cancer centers. Together, they shape go-to-market strategies and implementation with scientific and commercial precision. We extend our expertise with a proprietary network that delivers real-time insights from oncology pharmacy experts at approximately 100 leading cancer centers, bringing unmatched access intelligence to every engagement.